Position of the Transparency Council – Kaftrio (ivacaftor + tezacaftor + elexacaftor)

At its meeting on 28 October 2024, the Transparency Council adopted position No. 116/2024 on the evaluation of the drug Kaftrio (ivacaftor + tezacaftor + elexacaftor) under the drug program B.112 “Treatment of patients with cystic fibrosis (ICD-10: E84)”

Publication of the position >>